This programme will give you an invaluable overview of the Pharmaceutical industry, from discovery of the molecule through development to marketing
20 May 2019
& 21 Oct 2019
GBP 699 599 *
EUR 979 839 *
USD 1,090 934 *
* When you book before 12 Apr
This programme will give you an invaluable overview, refresher and update on the pharmaceutical and biotechnology industries, from discovery of the molecule through development to marketing. It will provide a step-by-step understanding of the main areas of drug development and will discuss the roles and responsibilities of key staff involved. You will be given a comprehensive glossary of the most commonly used industry terms, which will be an invaluable reference to help you
get to grips with the technical terminology and jargon.
This meeting runs back-to-back with An Essential Overview of the Medical Devices Industry and there is a further £100/€140 discount when booked with An Essential Overview of the Pharmaceutial and Biotech Industries.
To find out more call Customer Services on +44 (0)20 7749 4730 or e-mail firstname.lastname@example.org
All those wanting to achieve a better understanding of how the pharma/biotech industries work. The course will be particularly helpful for those wanting to understand what other departments do, for new staff working in the industry and for non-scientific and administrative personnel.
How the pharma/biotech industries develop medicines
Demystifying the jargon and terminology
What are the roles and responsibilities of the people in the pharma/biotech industries?
How are medicines marketed and sold?
Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years’ experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including “The Planning of International Drug Development”, in the Clinical Research Manual, Euromed and the “Impact of Brexit”, RQA Journal 2017.